Goldman Sachs Downgrades Ultragenyx Pharmaceutical to Neutral, Lowers Price Target to $25

Benzinga Newsdesk www.benzinga.com Negative 90.6%

Neg 90.6% Neu 0% Pos 0%

Goldman Sachs analyst Salveen Richter downgrades Ultragenyx Pharmaceutical (NASDAQ:RARE) from Buy to Neutral and lowers the price target from $61 to $25.